ArticleClinical and experimental medicine2025
Prognostic value of tumor microenvironment-based molecular subtypes in hepatocellular carcinoma patients undergoing surgery for spinal metastases: refining conventional scoring systems.
Article in Clinical and experimental medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) has a poor prognosis, particularly with spinal metastases. Current prognostic scores (e.g., Revised Tokuhashi, New England Spinal Metastasis Score) lack integration of tumor microenvironment (TME)-based molecular subtypes, limiting their utility in precision medicine. This study evaluated the prognostic value of these subtypes and whether they enhance established scoring systems. In a single-center retrospective cohort of 117 HCC patients undergoing surgery for spinal metastases (2009-2024), patients were stratified into three TME subtypes: immune-inflamed (n = 39), immune-excluded (n = 53), and immune-desert (n = 25). Overall survival (OS) was analyzed using Kaplan-Meier and Cox regression. The discriminative ability of four prognostic scores was assessed with time-dependent ROC curves. Recursive partitioning analysis (RPA) integrated molecular subtypes with clinical scores to develop novel decision trees. Median OS for the cohort was 13.1 months. TME subtype was a powerful independent prognostic factor, with immune-inflamed, immune-excluded, and immune-desert subtypes showing median OS of 17.2, 12.1, and 8.8 months, respectively (P < 0.001). Multivariable analysis confirmed this association (e.g., immune-desert aHR = 9.52, P < 0.001). The Revised Tokuhashi score showed the highest baseline discriminative ability for 1-year survival (AUROC = 0.726). Integrating TME subtype and postoperative systemic therapy significantly improved predictive accuracy across all models (AUROCs > 0.92). RPA generated clinically actionable decision trees, defining three distinct prognostic groups. TME-based molecular subtypes are critical independent survival determinants in HCC with spinal metastases. Their integration with clinical scores using RPA produces highly accurate predictive models and practical decision aids, advocating for a biology-augmented approach to personalize patient management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.